Jun 12, 2019
The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first tim...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper